Condition: Leukemia, Lymphoblastic · Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.
This description comes directly from the study's public registry record.
Oriana Nanni, Dr · +39 0543739100 · oriana.nanni@irst.emr.it
Anna Ferrari, Dr · 0543739909 · anna.ferrari@irst.emr.it
Always discuss trial participation with your own doctor first.
| Irst Irccs | Meldola, FC, Italy | Recruiting |
| Ospedale S. Maria delle Croci RAVENNA | Ravenna, RA, Italy | Recruiting |
| Ospedale Infermi | Rimini, RN, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06919393